Key result
Statin use in patients with depression was associated with lower mortality over 12 months (aOR 0.66-0.67; 99% CI 0.60-0.73) and did not increase adverse events.
Why the study?
NICE guidance endorses statins for broader populations including those with severe mental illness, but the safety and risk/benefit balance of statins in depression is not established.
Does statin use reduce mortality and adverse events in primary care patients with first-episode depression?
Cohort (n=1,050,105)
Yes
Does statin use reduce mortality and adverse events in primary care patients with first-episode depression?
Effect estimate: aOR 0.66-0.67 (95% CI 0.60-0.73)
Statin use in patients with depression is safe and associated with lower all-cause mortality over 12 months, supporting current guidelines for broader statin prescription.
No takes yet. Share an insight, caveat, or question.
Supports statin safety in depression; leaves open causal mortality benefit pending randomized trials.
Giorgi et al. (2024) conducted a cohort in first-episode depression (n=1,050,105). Statin use vs. Non-users was evaluated on all-cause mortality and any adverse event measured at 2, 6 and 12 months (aOR 0.66-0.67, 95% CI 0.60-0.73). Statin use in patients with depression was associated with lower mortality over 12 months (aOR 0.66-0.67; 99% CI 0.60-0.73) and did not increase adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: